Publikation bearbeiten

Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study ( Zeitschriftenartikel )

Details ansehen

Ausw.	Sortierung	* Link
	1	https://dx.doi.org/10.1016/S2352-3026(17)30171-0